Showing 5281-5290 of 5771 results for "".
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- Essilor Vision Foundation Collaborates With Government of Maharashtra to Support a Free Vision Care Program for 2.5 Million Children in Needhttps://modernod.com/news/essilor-vision-foundation-collaborates-with-government-of-maharashtra-to-support-a-free-vision-care-program-for-2-5-million-children-in-need/2476283/Essilor Vision Foundation has announced the support of the program ‘Blindness Free Maharashtra’ launched by the Government of Maharashtra in collaboration with the not-for-profit organization Ratna Nidhi Trust. Through this initiative, approximately 2.5 million children from underserv
- Alcon Debuts iLux MGD Treatment System at SECOhttps://modernod.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/Alcon debuted the iLux MGD Treatment System at the SECO International 2019 annual meeting in New Orleans. The device, which received approval from the FDA in December 2017, helps eye care professionals provide comprehensive, in-office
- VSY Biotechnology and Carl Zeiss Meditec Settle Legal Disputeshttps://modernod.com/news/vsy-biotechnology-and-carl-zeiss-meditec-settle-legal-disputes/2476289/VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to the Tri-ED 611 IOL. The companies did not disclose the terms of the settlement.
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider
- Registration Now Open for Neuro-Optometric Rehabilitation Association Meetinghttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 19-20) and 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona. The
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- Heidelberg OCT2 Module Successfully Installed at the International Space Stationhttps://modernod.com/news/heidelberg-oct2-module-successfully-installed-at-the-international-space-station/2476295/Heidelberg Engineering announced that its Spectralis imaging platform with the company’s next-generation OCT2 Module has been successfully installed at the International Space Station (ISS) and is now fully operational. NASA launched the Spectralis with OCT2 Module to the ISS aboard the An
- Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible Hydra-PEG Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-on-several-lenses/2476297/Bausch + Lomb announced it has received 510(k) clearance for use of the Tangible Hydra-PEG custom contact lens coating technology with some of its leading Boston gas permeable (GP) materials, the Boston XO, Boston XO2, Boston EO, and Boston ES lenses, including th
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16